Selective stock-picking and conviction drove HB Biotech’s strong 2024 performance. Read our insights on navigating today’s ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

The CEO of obesity drug manufacturer Novo Nordisk and heads of other Danish companies were expected to discuss preparations ...

The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...

Three Australian fund managers who delivered double-digit returns over the past 10 years share their views on what’s next for ...

D-Wave Quantum's valuation model suggests potential 25-35% annual returns in base and bull cases. See why we are neutral on ...

Gov. Gavin Newsom in 2020 signed a law allowing California to manufacture its own insulin, an effort to bring down the cost ...

With major U.S. lenders and investment banks’ earnings now turned in, one message from the wave of financial results is clear ...

Investors could be encouraged by news from TSMC, which reported a surge in profit on strong demand for AI semiconductors.